by The Tutu Team | Oct 31, 2016 | Uncategorized
Mark Pegram, MD Though some clinicians may characterize the treatment landscape of HER2-positive breast cancer as overcrowded, Mark Pegram, MD, firmly believes that there is still much to learn in this space. “Just because we have a couple of antibodies in... by The Tutu Team | Oct 11, 2016 | Uncategorized
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor–positive advanced breast cancer, reported Hortobagyi et al at the 2016 European Society for... 